Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04895215 · ClinicalTrials.gov registry record · Phase 2
AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)
A Phase 2 study of Autism Spectrum Disorder (ASD), sponsored by Vertero Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
- 20
- Study locations
NCT04895215 is a Phase 2 study of Autism Spectrum Disorder (ASD) that has completed, run by Vertero Therapeutics. The registered enrollment target is 156 participants, above the 93-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT04895215, a Phase 2 study of Autism Spectrum Disorder (ASD), has completed, sponsored by Vertero Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AB-2004
Study Locations (20)
Florida
- CNS Solutions - Jacksonville
- CNS Solutions - Orlando
- University of South Florida - Tampa
Arizona
- Southwestern Autism Research and Resource Center - Phoenix
- University of Arizona - Tucson
California
- Cortica Marin - San Rafael
- Cortica Westlake - Westlake Village
New York
- Spectrum Neuroscience and Treatment Institute - New York
- Nathan S. Kline Institute for Psychiatric Research - Orangeburg
New South Wales
- Brain Mind Centre - Sydney
- Westmead Children's Hospital - Sydney
Alabama
- Harmonex Neuroscience Research - Dothan
Colorado
- IMMUNOe Research Centers - Centennial
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2021-08-02 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04895215
The ClinicalTrials.gov registry entry for NCT04895215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 93-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (68% higher). The listed sponsor is Vertero Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Autism Spectrum Disorder (ASD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04895215 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04895215 about?
NCT04895215 is a clinical study titled "AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)". The purpose of this study is to establish the potential benefits, safety, and tolerability of AB-2004 in participants with irritability associated with autism spectrum disorder.
What is the current status of trial NCT04895215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2021-08-02. Estimated completion is 2023-12-15.
What conditions does trial NCT04895215 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder (ASD).
What interventions are being tested in trial NCT04895215?
The interventions under investigation include: Placebo (DRUG), AB-2004 (DRUG).
Who is sponsoring clinical trial NCT04895215?
This trial is sponsored by Vertero Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04895215 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder (ASD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
RECRUITING · Phase 2
-
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
COMPLETED · Phase 2
-
ADAPT: Approach to Dance for Autism
RECRUITING · NA
-
External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms
RECRUITING · NA
-
Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study
RECRUITING · Phase 1
-
Sleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.